|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Nonalcoholic fatty liver disease: An overview of current insights in pathogenesis, diagnosis and treatment显示文摘Estimates of people suffering from overweight (one billion) and obesity (300 million) are increasing. The accumulation of triglycerides in the liver, in the absence of excess alcohol intake, has been described in the early sixties. It was not until 1980, however, that Ludwig et al named this condition nonalcoholic steatohepatitis (NASH). Subsequently, nonalcoholic fatty liver disease (NAFLD) has been used as a general name for conditions ranging from simple steatosis through steatohepatitis to end-stage liver disease (cirrhosis). Many studies have demonstrated the significant correlation with obesity and insulin resistance. Other studies have revealed a signifi- cant correlation between hepatic steatosis, cardiovascu- lar disease and increased intima-media thickness. WHO estimated that at least two million patients will develop cirrhosis due to hepatic steatosis in the years to come. Longitudinal cohort studies have demonstrated that those patients with cirrhosis have a similar risk to devel- op hepatocellular carcinoma as those with other causes of cirrhosis. Taken all together, NAFLD has become the third most important indication for liver transplantation. There- fore, training programmes in internal medicine, gastroen- terology and hepatology should stress the importance of diagnosing this entity and treat properly those at risk for developing complications of portal hypertension and con- comittant cardiovascular disease. This review will focus on the clinical characteristics, pathophysiology, imaging tech- niques and the readily available therapeutic options. | Tim CMA Schreuder Bart J Verwer Carin MJ van Nieuwkerk Chris JJ Mulder | 2008 | World Journal of Gastroenterology2008，14，16： | 35 |
| 2 | 戊型肝炎病毒Ⅳ型在300例急性肝炎中的感染比例显示文摘目的 调查戊型肝炎病毒 (HEV)Ⅳ型在北京地区的急性散发性肝炎中的分布。方法采用RT nPCR的方法检测 30 0例急性散发性肝炎患者中HEVRNA ,并对阳性产物进行克隆测序 ,然后对其基因型进行分析。结果 在 30 0例急性散发性肝炎患者中PCR阳性为 2 5例 ,测序证实 2 5例PCR阳性者中 ,2 4例为HEV的基因序列 ;其中 9例为HEVⅠ型 ,15例为HEVⅣ型 ,占HEV感染的 6 2 .5 %(15 / 14 )。结论 在北京地区的部分急性散发性肝炎中HEVⅣ型感染占戊型肝炎的较大比例。 | 蓝海云 王佑春 李卓 张华远 郝娃 辜文洁 林京香 李河民 Tim J Harrison | 2002 | 中华微生物学和免疫学杂志2002，22，3： | 24 |
| 3 | 戊型肝炎病毒Ⅳ型全基因序列的分析显示文摘目的 分析戊型肝炎病毒 (HEV)Ⅳ型的全基因序列以比较与其他基因型的差异。方法 设计PCR引物对全基因进行分片段扩增 ,并对两个末端采用末端快速扩增方法 (RACE)进行扩增 ,对扩增产物进行克隆及测序。结果 HEV T1全序与Ⅰ型、Ⅱ型和Ⅲ型的核苷酸同源性分别为(74.8~ 75 .5 ) %、74.5 %和 (75 .3~ 76 .3) %。ORF1与已报道的Ⅰ型、Ⅱ型和Ⅲ型氨基酸同源性分别为(85 .0~ 86 .7) %、85 .0 %和 (88.5~ 88.7) % ;ORF2与已报道的Ⅰ型、Ⅱ型和Ⅲ型的氨基酸同源性分别为 (91.6~ 92 .4) %、90 .1%和 (91.9~ 93.0 ) % ;ORF3与已报道的Ⅰ型、Ⅱ型和Ⅲ型的氨基酸同源性分别为 (75 .9~ 77.8) %、75 .0 %和 (79.6~ 83.3) %。结论 这一研究为今后发展戊型肝炎诊断试剂及戊型肝炎疫苗提供了新的、重要的分子生物学基础。 | 王佑春 张华远 李河民 Tim J Harrison | 2001 | 中华微生物学和免疫学杂志2001，21，2： | 22 |
| 4 | Current status of laparoscopic and robotic ventral mesh rectopexy for external and internal rectal prolapse显示文摘External and internal rectal prolapse with their affiliated rectocele and enterocele, are associated with debilitating symptoms such as obstructed defecation, pelvic pain and faecal incontinence. Since perineal procedures are associated with a higher recurrence rate, an abdominal approach is commonly preferred. Despite the description of greater than three hundred different procedures, thus far no clear superiority of one surgical technique has been demonstrated. Ventral mesh rectopexy(VMR) is a relatively new and promising technique to correct rectal prolapse. In contrast to the abdominal procedures of past decades, VMR avoids posterolateral rectal mobilisation and thereby minimizes the risk of postoperative constipation. Because of a perceived acceptable recurrence rate, good functional results and low mesh-related morbidity in the short to medium term, VMR has been popularized in the past decade. Laparoscopic or robotic-assisted VMR is now being progressively performed internationally and several articles and guidelines propose the procedure as the treatment of choice for rectal prolapse. In this article, an outline of the current status of laparoscopic and robotic ventral mesh rectopexy for the treatment of internal and external rectal prolapse is presented. | Jan J van Iersel Tim JC Paulides Paul M Verheijen John W Lumley Ivo AMJ Broeders Esther CJ Consten | 2016 | World Journal of Gastroenterology2016，22，21： | 20 |
| 5 | 血清乙型肝炎病毒DNA阳性与原发性肝癌危险性关系的前瞻性队列研究显示文摘目的探讨血清HBV DNA阳性与原发性肝癌的关系。方法以分层抽样方法对广西隆安县12个乡镇30~55岁农村居民抽样,采静脉血,酶联免疫吸附试验检测HBsAg,套式聚合酶链反应检测HBV DNA。根据HBsAg和DNA检测结果,将研究对象分为HBsAg(+)/HBvDNA(+)组(A组)和HBsAg(+)/HBVDNA(-)组(B组);根据1:1匹配原则,从本村屯HBsAg(-)者中为前两组观察对象挑选对照,组成HBsAg阴性对照组(C组),对这3组人群进行4年的前瞻性跟踪随访。卡方检验对各组及各因素的发病率进行统计分析,然后用Cox比例风险模型分析与PLC有关的危险因素,用后退法对数值进行迭代分析。结果30~55岁人群HBsAg阳性率为14.52%(3975/27379),HBsAg阳性者HBV DNA阳性率为40.35%(1604/3975)。A、B两组总的肝癌发病率为672.45/10万人年,明显高于C组的17.19/10万人年(P〈0.01),相对危险度为39.123,95%可信因司为9.018~159.146。A组肝癌发病率为984.03/10万人年,显明高于C组的324.38/10万人年(P〈0.01),相对危险度为3.034,95%可信区间为1.795~5.125。对A、B两组进行肝癌危险因素的多因素Cox模型分析,结果表明性别、年龄、血清HBV DNA阳性、肝癌家族史和以玉米为主食均为肝癌的危险因素。结论血清HBV DNA阳性可增加HBsAg阳性者的肝癌危险性。 | 陈钦艳 董柏青 杨进业 韦少超 方孔雄 王学燕 方钟燎 Caroline Sabin Tim J Harrison | 2009 | 中华肝脏病杂志2009，17，12： | 10 |
| 6 | 隆安县乙型肝炎病毒感染的分子流行病学研究显示文摘目的 了解隆安县乙型肝炎病毒(HBV)的分子流行病学特征。方法 以分层抽样方法对隆安县全县12个乡、镇108个自然村30~50岁居民进行调查,抽取静脉血,用酶联免疫吸附法(ELISA)检测乙型肝炎表面抗原(HBsAg),用套式聚合酶链反应(nPCR)对HBsAg阳性者检测血清HBVDNA。结果 在27379名受检者中,HBsAg阳性率为14.52%,各乡、镇的感染率不尽相同,平原片显著高于山区和丘陵片;男、女阳性率分别为16.66%和12.60%,男性明显高于女性;各年龄组HBsAg阳性率随年龄增长而呈下降趋势。在3975名HBsAg阳性者中,HBVDNA阳性率40.35%,阳性率在各乡、镇的分布也不一致;男、女HBVDNA阳性率分别为42.82%和37.44%,男性显著高于女性;也呈现随年龄增长而下降趋势。结论 隆安县仍是我区乙肝病毒高流行区,应加强防治。 | 陈钦艳 董柏青 谭明杰 葛莲英 杨进业 韦少超 方孔雄 黄坚 李荣成 王学燕 Caroline Sabin 方钟燎 Tim J Harrison | 2007 | 应用预防医学2007，13，3： | 7 |
| 7 | 广西地区乙型肝炎病毒无症状携带者乙型肝炎病毒前C区突变分析显示文摘目的 调查广西地区乙型肝炎病毒 (HBV)无症状携带者HBV前C区基因突变株的流行情况。方法 用套式聚合酶链反应 (nPCR)对 77例广西南部、北部地区人群HBV无症状携带者血清HBV前C区进行扩增 ,阳性者用直接测序法进行序列分析。结果 39例HBsAg无症状携带者血清HBVDNA阳性 ,阳性率为 5 0 .7% (39 77) ,突变株出现率为 2 2 .1% (17 77)。南部地区阳性率为5 5 .6 % (2 0 36 ) ,其中 6份标本出现突变株 ,占 30 % ,常见的突变类型是nt185 8位发生点突变 (T→C) ,只有一份标本在nt1896发生点突变 (G→A) ,导致终止密码产生 ,该标本同时伴有nt1837点突变(A→G) ;北部地区阳性率为 4 6 .3% (19 4 1) ,其中有 11份标本出现突变株 ,占 5 7.9% ,常见的突变类型是nt1896位发生点突变 (G→A) ,这些标本中有 4份同时在nt184 6发生点突变 (A→T) ,2份同时在nt186 2发生点突变 (G→T) ;标本 734分别在nt185 6、185 8发生点突变 (C→T、T→C)。结论 广西地区HBV无症状携带者HBV前C区突变株的流行率居全国中等水平 ,广西南部、北部是否存在主要突变类型不同值得进一步研究。 | 方钟燎 庄辉 杨进业 葛宪民 王学燕 龚健 李荣成 Roger Ling Tim J Harrison | 2002 | 中华流行病学杂志2002，23，6： | 6 |
| 8 | 乙肝病毒A1762、G1764双突变是筛选男性HBsAg携带者肝癌最高危人群的生物学标记显示文摘目的探讨乙肝病毒A1762、G1764双突变是否可作为筛选HBsAg携带者肝癌最高危人群的生物学标记。方法对2 258名乙肝病毒无症状携带者进行前瞻性队列研究,其中HBV A1762、G1764双突变株组1 261人,野毒株组997人,跟踪随访队列,每6个月1次对观察对象抽血进行甲胎蛋白(AFP)检测及B超体检以检查肝癌发病情况。结果观察48个月,2 258名乙肝病毒无症状携带者中,共发生肝癌72例,突变株组64例,野毒株组8例,发病率分别为932.2/10万人年和203.5/10万人年,两组发病率差异有统计学意义(P<0.001),相对危险度(RR)为4.58。突变株组男性发病率1 827.8/10万人年,明显高于野毒株组的180.5/10万人年,两者比较差异有统计学意义(P<0.001),相对危险度为10.13。92.5%的男性病例有双突变;突变株组女性发病率为686.6/10万人年,高于野毒株组的233.3/10万人年,两组比较差异有统计学意义(P<0.05),但相对危险度仅为2.94。结论双突变是筛选男性HBsAg携带者中肝癌最高危人群的很好生物学标记,但对女性筛选肝癌高危人群的意义不如男性。 | 王学燕 李国坚 董柏青 杨进业 陈钦艳 方孔雄 黄坚 韦少超 方钟燎 Caroline A Sabin Tim J Harrison | 2011 | 广西医学2011，33，2： | 5 |
| 9 | 乙肝肝硬化患者HBV前C区和基本核心基因启动子序列分析显示文摘用套式PCR(nPCR)对 3 5例肝硬化患者血清HBV前C区和基本核心基因启动子 (BCP)进行扩增 ,阳性者用直接测序法进行序列分析。结果 2 3例HBVDNA阳性 ,阳性率为 65 7% ( 2 3 / 3 5 ) ,无正常序列标本 ,与e抗原产生有关的突变 :nt1762、1764双突变 (AT、GA) ,占 73 9% ( 17/ 2 3 ) ;nt1896点突变 (GA) ,导致终止密码产生 ,占2 1 7% ( 5 / 2 3 ) ;nt185 8点突变 (TC) ,占 2 1 7% ,其中标本 417、42 6、43 0同时在nt 185 6发生点突变 (CT)。其它的突变有nt1799点突变 (CG) ,占 47 8% ( 11/ 2 3 ) ,为无义突变 ;有 6例在nt1846发生点突变AT ,4例nt180 2 - 180 4发生突变 (TTCCGT) ;4例nt175 2位点突变 (AG) ;标本 43 2在nt175 1插入TG导致移码突变 ,并在nt1774- 1874发生缺失突变。说明HBVBCP和前C突变株在肝硬化患者中很常见 。 | 方钟燎 庄辉 杨进业 葛宪民 王学燕 龚健 李荣成 王佑春 Roger Ling Tim J Harrison | 2003 | 临床肝胆病杂志2003，19，3： | 5 |
| 10 | Refining pathological evaluation of neoadjuvant therapy for adenocarcinoma of the esophagus显示文摘AIM:To assess tumour regression grade(TRG)and lymph node downstaging to help define patients who benefit from neoadjuvant chemotherapy.METHODS:Two hundred and eighteen consecutive patients with adenocarcinoma of the esophagus or gastro-esophageal junction treated with surgery alone or neoadjuvant chemotherapy and surgery between 2005and 2011 at a single institution were reviewed.Triplet neoadjuvant chemotherapy consisting of platinum,fluoropyrimidine and anthracycline was considered for operable patients(World Health Organization performance status≤2)with clinical stage T2-4 N0-1.Response to neoadjuvant chemotherapy(NAC)was assessed using TRG,as described by Mandard et al.In addition lymph node downstaging was also assessed.Lymph node downstaging was defined by cN1 at diagnosis:assessed radiologically(computed tomography,positron emission tomography,endoscopic ultrasonography),then pathologically recorded as N0 after surgery;ypN0 if NAC given prior to surgery,or pN0if surgery alone.Patients were followed up for 5 years post surgery.Recurrence was defined radiologically,with or without pathological confirmation.An association was examined between t TRG and lymph node downstaging with disease free survival(DFS)and a comprehensive range of clinicopathological characteristics.RESULTS:Two hundred and eighteen patients underwent esophageal resection during the study interval with a mean follow up of 3 years(median follow up:2.552,95%CI:2.022-3.081).There was a 1.8%(n=4)inpatient mortality rate.One hundred and thirty-six(62.4%)patients received NAC,with 74.3%(n=101)of patients demonstrating some signs of pathological tumour regression(TRG 1-4)and 5.9%(n=8)having a complete pathological response.Forty four point one percent(n=60)had downstaging of their nodal disease(cN1 to ypN0),compared to only 15.9%(n=13)that underwent surgery alone(pre-operatively overstaged:cN1 to pN0),(P<0.0001).Response to NAC was associated with significantly increased DFS(mean DFS;TRG 1-2:5.1years,95%CI:4.6-5.6 vs TRG 3-5:2.8 years,95%CI:2.2-3.3,P<0.0001).Nodal down-staging conferred a significant DFS advantage for those patients with a poor primary tumour response to NAC(median DFS;TRG 3-5 and nodal down-staging:5.533 years,95%CI:3.558-7.531 vs TRG 3-5 and no nodal down-staging:1.114 years,95%CI:0.961-1.267,P<0.0001).CONCLUSION:Response to NAC in the primary tumour and in the lymph nodes are both independently associated with improved DFS. | Fergus Noble Luke Nolan Adrian C Bateman James P Byrne Jamie J Kelly Ian S Bailey Donna M Sharland Charlotte N Rees Timothy J Iveson Tim J Underwood Andrew R Bateman | 2013 | World Journal of Gastroenterology2013，19，48： | 4 |
| 11 | Liver Transplantation for Nonresectable Liver Metastases From Colorectal Cancer显示文摘 | Morten Hagness Aksel Foss P?l-Dag Line Tim Scholz P?l Foyn J?rgensen Bjarte Fosby Kirsten Muri Boberg ?ystein Mathisen Ivar P. Gladhaug Tor Skatvedt Egge Steinar Solberg John Hausken Svein Dueland | 2013 | Annals of Surgery2013，，5： | 4 |
| 12 | 澳大利亚人乳头状瘤病毒疫苗计划实施5年对年轻人群生殖器疣患病情况的影响:国家调查数据分析显示文摘目的评估2007年中开始的澳大利亚人乳头状瘤病毒(HPV)疫苗计划对生殖器疣患病情况的影响。设计国家调查数据趋势分析。数据来源数据收集于2004--2011年度澳大利亚8所性健康服务机构;其中2所最大的临床中心收集了自我报告的本中心2009年度HPV疫苗现状。研究对象2004--2011年度首次就诊的85770名澳大利亚出生的国民;其中7686(9.0%)名患生殖器疣。主要结局测量比较前疫苗时期(2004—2007年中)和疫苗时期(2007年中-2001年末)不同人群生殖器疣新发病率变化趋势。结果疫苗时期21岁以下和21~30岁女性诊断患有生殖器疣的比例明显下降,发病率分别从2007年度的11.5%和11.3%下降至2011年度的0.85%和3.1%,P均〈0.001。在30岁以上的女性中未发现发病率的明显下降。在21岁以下和21~30岁异性恋男性人群中疫苗时期生殖器疣的发病率较前疫苗时期明显下降,分别由2007年度12.1%和18.2%下降至2011年度2.2%和8.9%,P均〈0.001。30岁以上的异性恋男性人群中发病率无明显下降。2011年235名21岁以下女性在使用HPV疫苗后无新发生殖器疣病例。结论年轻女性生殖器疣发病率的显著下降和2011年度部分年轻女性使用疫苗后的零发病率,说明HPV疫苗获得实验室外的良好功效。异性恋男性生殖器疣发病率的显著下降可能是由于群体免疫所致。 | Hammad Ali,lecturer Basil Donovan, professor HandanWand,senior lecturer Tim R H Read, sexual health physician David G Regan,senior lecturer Andrew E Grulich, professor Christopher K FaMey, professor Rebecca J Guy, associate professor 尹婕(译) 潘凌亚(校) | 2013 | 英国医学杂志中文版2013，16，4： | 4 |
| 13 | 隆安县乙肝病毒无症状携带者HBV前S基因缺失突变的研究显示文摘目的了解肝癌高发区隆安县乙型肝炎病毒(HBV)前S基因缺失突变株的流行情况。方法HBV表面抗原(HBsAg)无症状携带者从我们隆安县研究队列中选择,用套式聚合酶链反应对研究对象血清HBV前S基因扩增和序列分析。结果在66例标本中9例出现前S基因缺失突变,占13.6%(9/66)。9例缺失突变均为框内突变,其中7例突变发生在或涉及前S2区的5'末端。男6例、女3例出现前S基因缺失突变,但男女间突变率(12.0%,6/50与18.8%,3/16)差异无统计学意义(χ2=0.709,P>0.10);前S基因缺失突变率在基因型B、基因型C和重组基因型之间差异无统计学意义(χ2=0.002,P>0.95)。结论肝癌高发区隆安县居民HBV无症状携带者前S基因缺失突变率较高,这种突变与肝癌的关系值得进一步探讨。 | 王学燕 李国坚 董柏青 陈钦艳 方孔雄 杨进业 黄坚 韦少超 方钟燎 Caroline A Sabin Tim J Harrison | 2010 | 广西医学2010，32，2： | 4 |
| 14 | Ampullary cancer of intestinal origin and duodenal cancer-A logical clinical and therapeutic subgroup in periampullary cancer显示文摘Periampullary cancers include pancreatic, ampullary, biliary and duodenal cancers. At presentation, the majority of periampullary tumours have grown to involve the pancreas, bile duct, ampulla and duodenum. This can result in difficulty in defining the primary site of origin in all but the smallest tumors due to anatomical proximity and architectural distortion. This has led to variation in the reported proportions of resected periampullary cancers. Pancreatic cancer is the most common cancer resected with a pancreaticoduodenectomy followed by ampullary(16%-50%), bile duct(5%-39%), and duodenal cancer(3%-17%). Patients with resected duodenal and ampullary cancers have a better reported median survival(29-47 mo and 22-54 mo) compared to pancreatic cancer(13-19 mo). The poorer survival with pancreatic cancer relates to differences in tumour characteristics such as a higher incidence of nodal, neural and vascular invasion. While small ampullary cancers can present early with biliary obstruction, pancreatic cancers need to reach a certain size before biliary obstruction ensues. This larger size at presentation contributes to a higher incidence of resection margin involvement in pancreatic cancer. Ampullary cancers can be subdivided into intestinal or pancreatobiliary subtype cancers with histomolecular staining. This avoids relying on histomorphology alone, as even some poorly differentiated cancers preserve the histomolecular profile of their mucosa of origin. Histomolecular profiling is superior to anatomic location in prognosticating survival. Ampullary cancers of intestinal subtype and duodenal cancers are similar in their intestinal origin and form a logical clinical and therapeutic subgroup of periampullary cancers. They respond to 5-FU based chemotherapeutic regimens such as capecitabine-oxaliplatin. Unlike pancreatic cancers, KRAS mutation occurs in only approximately a third of ampullary and duodenal cancers. Future clinical trials should group ampullary cancers of intestinal origin and duodenal cancers together given their similarities and their response to fluoropyrimidine therapy in combination with oxaliplatin. The addition of anti-epidermal growth factor receptor therapy in this group warrants study. | Manju D Chandrasegaram Anthony J Gill Jas Samra Tim Price John Chen Jonathan Fawcett Neil D Merrett | 2017 | World Journal of Gastrointestinal Oncology2017，9，10： | 4 |
| 15 | 广西原发性肝癌患者HBV-DNA核心基因启动子突变的研究显示文摘用套式PCR(nestedPCR)对广西16例原发性肝癌患者血清HBVDNA核心基因启动子进行扩增,阳性者用Sanger氏DNA测序法进行序列分析。结果表明14例患者PCR阳性,阳性率为87.50%,其中除唯一的HBeAg阳性者(C23)外,均具有双突变(即第1762位A→T,1764位G→T核苷酸的点突变),而且所有的血清标本在这突变点周围均有不同部位的点突变,但在标本C23整个启动子中,未发现任何碱基突变。本文对这种突变株可能的致癌机理进行了讨论。 | 方钟燎 王树声 麦威 黄春松 Roger Ling Tim J Harrison | 1997 | 广西预防医学1997，3，4： | 3 |
| 16 | 肝癌组织中HBV核心基因启动子突变的研究显示文摘为深入了解乙肝病毒 (HBV)致癌机理 ,用套式PCR对广西 14例血清HBVDNA阳性的原发性肝癌患者癌组织、10例乙型病毒性肝炎患者血清及 10例乙肝病毒无症状携带者血清HBV核心基因启动子进行扩增 ,阳性者用Sanger氏双脱氧法做序列分析 ,发现肝癌组织 10例PCR阳性 ,阳性率 71.4 % ,所有PCR阳性标本的整合体均有乙肝病毒核心基因启动子双突变序列 (nt 176 2A→T ,176 4G→A) ,并且在其周围各序列都有不同部位的点突变 ,标本C14核苷酸的缺失突变高达10个。乙肝患者 6例PCR阳性 ,其中 3例乙肝病毒核心基因启动子发生双突变。无症状携带者中 4例PCR阳性 ,其中仅 1例发生双突变。结果提示乙肝病毒核心基因启动子双突变在肝癌患者中较常见 ,肝炎患者次之 ,无症状携带者居最后。 | 方钟燎 杨进业 王学燕 庄辉 Roger Ling Tim J Harrison | 2000 | 中国病毒学2000，15，3： | 3 |
| 17 | Optimal Contraction Intensity During Proprioceptive Neuromuscular Facilitation for Maximal Increase of Range of Motion显示文摘 | Peter W Sheard Tim J Paine | 2010 | Journal of Strength and Conditioning Research2010，，2： | 2 |
| 18 | Global review and synthesis of trends in observed terrestrial near-surface wind speeds: Implications for evaporation显示文摘 | Tim R. McVicar Michael L. Roderick Randall J. Donohue Ling Tao Li Thomas G. Van Niel Axel Thomas Jürgen Grieser Deepak Jhajharia Youcef Himri Natalie M. Mahowald Anna V. Mescherskaya Andries C. Kruger Shafiqur Rehman Yagob Dinpashoh | 2011 | Journal of Hydrology2011，，： | 2 |
| 19 | Biochar and the Nitrogen Cycle: Introduction显示文摘 | Clough Tim J Condron Leo M | 2010 | Journal of Environmental Quality2010，，4： | 2 |
| 20 | HBsAg携带者配偶乙型肝炎病毒感染状况调查显示文摘目的了解广西乙型肝炎病毒(HBV)性传播状况。方法对我们2004年建立的隆安研究队列HBsAg无症状携带者的配偶采静脉血收集血清,用酶联免疫吸附试验检测HBV血清学标志物。结果 217名研究对象中,96.8%(210/217)有过去或目前感染乙肝病毒的标记,其中32例HBsAg阳性,阳性率为14.7%(32/217),男、女阳性率分别为15.4%(14/91)和14.3%(18/126),差异无统计学意义(χ2=0.051,P>0.05);107例HBsAb阳性,阳性率为49.3%(107/217);一名男性HBsAg和HBsAb同时阳性;有79例HBsAg,anti-HBs and HBeAg阴性,这79例要么抗-HBc和抗-HBe同时阳性,要么单项阳性,但都是HBVDNA阴性;有7人(包括男性3人、女性4人)没有任何乙肝感染标记,包括HBVDNA阴性。另外,122名HBVDNA阳性的HBsAg携带者其配偶(研究对象)有14人HBsAg阳性;95名HBVDNA阴性的HBsAg携带者其配偶有18人HBsAg阳性,两者阳性率无统计学差异(χ2=2.372,P>0.05)。HBeAg阴、阳性的HBsAg携带者其配偶的HBsAg阳性率分别为15.61%(27/173)和11.76%(4/34),两者也无统计学差异(χ2=0.093,P>0.05)。结论配偶因密切接触HBsAg携带者而受HBV感染的机会比一般人群大,但性别、病毒量和HBeAg不影响其配偶感染HBV的机会。 | 王学燕 李国坚 杨进业 陈钦艳 黄坚 方孔雄 方钟燎 Caroline A Sabin Tim J Harrison | 2010 | 应用预防医学2010，16，6： | 2 |
您所在的机构暂未开通此部分的功能，请联系管理员